Search

Displaying results 8161 - 8170 of 10000 in total
  1. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    The study is expected to be completed in March 2021.[L17398] … [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies.

  2. Drug

    AZD-4877

    go.drugbank.com/drugs/DB11671
    Investigational

    AZD4877 has been used in trials studying the treatment of NHL, Tumors, Cancer, Lymphoma, and Neoplasms, among others.

  3. Drug

    Rapastinel

    go.drugbank.com/drugs/DB11801
    Investigational

    Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).

  4. Drug

    B27PD

    go.drugbank.com/drugs/DB16289
    Investigational

    B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).

  5. Drug

    Vicagrel

    go.drugbank.com/drugs/DB16349
    Investigational

    Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

  6. Drug

    AVI-014

    go.drugbank.com/drugs/DB17086
    Investigational

    AVI-014 is an egg white-derived transgenic, glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).[A274441]

  7. Drug

    ENB-003

    go.drugbank.com/drugs/DB17340
    Investigational

    ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.

    Synonyms: ENB 003
  8. Drug

    MORAb-066

    go.drugbank.com/drugs/DB17347
    Investigational

    It is being investigated in pancreatic cancer.

  9. Drug

    AVP-21D9

    go.drugbank.com/drugs/DB17798
    Investigational

    AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]

  10. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR